Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Miolo, Gianmaria ^a   Muraro, Elena ^a   Martorelli, Debora ^a   Lombardi, Davide ^a   Scalone, Simona ^a   Spazzapan, Simon ^a   Massarut, Samuele ^a   Perin, Tiziana ^a   Viel, Elda ^a   Comaro, Elisa ^a   Talamini, Renato ^a   Bidoli, Ettore ^a   Turchet, Elisa ^a   Crivellari, Diana ^a   Dolcetti, Riccardo ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Breast cancer; HER2; Immune response; Neoadjuvant chemotherapy; Trastuzumab

Indexed keywords

ANTHRACYCLINE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FC RECEPTOR; FC RECEPTOR IIIA; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CYTOKINE; FCGR3A PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ADJUVANT THERAPY; ADULT; AGED; ALLELE; ALOPECIA; ANEMIA; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EPIGASTRIC PAIN; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FLUSHING; GENE OVEREXPRESSION; GENOTYPE; HEART LEFT VENTRICLE FAILURE; HORMONAL THERAPY; HUMAN; HYPERTRANSAMINASEMIA; IN VITRO STUDY; LEG EDEMA; LEUKOPENIA; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL DISEASE; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PROTEIN BLOOD LEVEL; PROTEIN POLYMORPHISM; SINGLE BLIND PROCEDURE; SKIN TOXICITY; TREATMENT OUTCOME; TUMOR IMMUNITY; UNSPECIFIED SIDE EFFECT; WEAKNESS; BLOOD; BREAST NEOPLASMS; CANCER STAGING; CLINICAL TRIAL; FEMALE; GENETIC POLYMORPHISM; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MORTALITY; NEOADJUVANT THERAPY; PATHOLOGY; YOUNG ADULT;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYTOKINES; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PACLITAXEL; POLYMORPHISM, GENETIC; RECEPTOR, ERBB-2; RECEPTORS, IGG; TRASTUZUMAB; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84924738397     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-954     Document Type: Article

References (32)

1. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN: Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005, 23:3676-3685. 10.1200/JCO.2005.07.032.
2. Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, Pusztai L, Green MC, Singletary SE, Hunt KK, Sahin AA, Esteva F, Symmans WF, Ewer MS, Buchholz TA, Hortobagyi GN: Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 2007, 13:228-233. 10.1158/1078-0432.CCR-06-1345.
3. Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, Zambetti M, Vazquez F, Byakhow M, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Baronio R, Feyereislova A, Barton C, Valagussa P, Baselga J: Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010, 375:377-384. 10.1016/S0140-6736(09)61964-4.
4. Gianni L, Eiermann W, Semiglazov V, Lluch A, Tjulandin S, Zambetti M, Moliterni A, Vazquez F, Byakhov MJ, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Magazzù D, Heinzmann D, Steinseifer J, Valagussa P, Baselga J: Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol 2014,15(6):640-647. 10.1016/S1470-2045(14)70080-4.
5. Untch M, Fasching PA, Konecny GE, Hasmüller S, Lebeau A, Kreienberg R, Camara O, Müller V, du Bois A, Kühn T, Stickeler E, Harbeck N, Höss C, Kahlert S, Beck T, Fett W, Mehta KM, von Minckwitz G, Loibl S: Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol 2011, 29:3351-3357. 10.1200/JCO.2010.31.4930.
6. Tsavaris N, Kosmas C, Vadiaka M, Kanelopoulos P, Boulamatsis D: Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer 2002, 87:21-27. 10.1038/sj.bjc.6600347.
7. Staaf J, Ringner M, Vallon-Christersson J, Jönsson G, Bendahl PO, Holm K, Arason A, Gunnarsson H, Hegardt C, Agnarsson BA, Luts L, Grabau D, Fernö M, Malmström PO, Johannsson OT, Loman N, Barkardottir RB, Borg A: Identification of subtypes in human epidermal growth factor receptor 2-positive breast cancer reveals a gene signature prognostic of outcome. J Clin Oncol 2010, 28:1813-1820. 10.1200/JCO.2009.22.8775.
8. Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, Cabaret V, Fermeaux V, Bertheau P, Garnier J, Jeannin JF, Coudert B: Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 2006, 94:259-267. 10.1038/sj.bjc.6602930.
9. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, Laccabue D, Zerbini A, Camisa R, Bisagni G, Neri TM, Ardizzoni A: Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008, 26:1789-1796. 10.1200/JCO.2007.14.8957.
10. Tamura K, Shimizu C, Hojo T, Akashi-Tanaka S, Kinoshita T, Yonemori K, Kouno T, Katsumata N, Ando M, Aogi K, Koizumi F, Nishio K, Fujiwara Y: FcgammaR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer. Ann Oncol 2011, 22:1302-1307. 10.1093/annonc/mdq585.
11. Varchetta S, Gibelli N, Oliviero B, Nardini E, Gennari R, Gatti G, Silva LS, Villani L, Tagliabue E, Ménard S, Costa A, Fagnoni FF: Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res 2007, 67:11991-11999. 10.1158/0008-5472.CAN-07-2068.
12. Nolen BM, Marks JR, Ta'san S, Rand A, Luong TM, Wang Y, Blackwell K, Lokshin AE: Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer. Breast Cancer Res 2008, 10:R45. 10.1186/bcr2096.
13. Muraro E, Martorelli D, Turchet E, Miolo G, Scalone S, Comaro E, Talamini R, Mastorci K, Lombardi D, Perin T, Carbone A, Veronesi A, Crivellari D, Dolcetti R: A different immunologic profile characterizes patients with HER-2-overexpressing and HER-2-negative locally advanced breast cancer: implications for immune-based therapies. Breast Cancer Res 2011, 13:R117. 10.1186/bcr3060.
14. Fisher ER, Wang J, Bryant J, Fisher B, Mamounas E, Wolmark N: Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer 2002, 95:681-695. 10.1002/cncr.10741.
15. Kim MM, Allen P, Gonzalez-Angulo AM, Woodward WA, Meric-Bernstam F, Buzdar AU, Hunt KK, Kuerer HM, Litton JK, Hortobagyi GN, Buchholz TA, Mittendorf EA: Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer. Ann Oncol 2013, 24:1999-2004. 10.1093/annonc/mdt131.
16. Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gómez H, Dinh P, Fauria K, Van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horváth Z, Coccia-Portugal M, Domont J, Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch M, Gelber RD, Piccart-Gebhart M, NeoALTTO Study Team: Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012, 379:633-640. 10.1016/S0140-6736(11)61847-3.
17. Norris CF, Pricop L, Millard SS, Taylor SM, Surrey S, Schwartz E, Salmon JE, McKenzie SE: A naturally occurring mutation in Fc gamma RIIA: a Q to K127 change confers unique IgG binding properties to the R131 allelic form of the receptor. Blood 1998,91(2):656-662.
18. Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi G, Szado T, Ratnayake J, Ross G, Valagussa P: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012, 13:25-32. 10.1016/S1470-2045(11)70336-9.
19. Burstein HJ, Harris LN, Gelman R, Lester SC, Nunes RA, Kaelin CM, Parker LM, Ellisen LW, Kuter I, Godd MA, Christian RL, Kennedy PR, Borges VF, Bunnel CA, Younger J, Smith BL, Winer EP: Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol 2003, 21:46-53. 10.1200/JCO.2003.03.124.
20. John M, Hinke A, Stauch M, Wolf H, Mohr B, Hindenburg HJ, Papke J, Schlosser J, FAKT Study Group: Weekly paclitaxel plus trastuzumab in metastatic breast cancer pretreated with anthracyclines-a phase II multipractice study. BMC Cancer 2012, 12:165. 10.1186/1471-2407-12-165.
21. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J, Breast Cancer International Research Group: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011, 365:1273-1283. 10.1056/NEJMoa0910383.
22. Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Guo H, Hudis CA, Krop IE, Burstein HJ, Winer EP: Adjuvant paclitaxel and trastuzumab for node-negative HER2 + Breast Cancer [abstract]. Sabcs 2013., (abstr S1-04):
23. Loibl S, von Minckwitz G, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Hanusch C, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Konecny G, Denkert C, Nekljudova V, Mehta K, Untch M: pCR as a surrogate in HER2-positive patients treated with Trastuzumab. Cancer Res 2011.,71(24 suppl; abstr S5-4):
24. von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Konecny GE, Denkert C, Nekljudova V, Mehta K, Loibl S: Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012, 30:1796-1804. 10.1200/JCO.2011.38.8595.
25. Chen X, Ye G, Zhang C, Li X, Chen Y, Xie X, Zheng H, Cao Y, Wu K, Ni D, Tang J, Wei Z, Shen K: Superior outcome after neoadjuvant chemotherapy with docetaxel, anthracycline, and cyclophosphamide versus docetaxel plus cyclophosphamide: results from the NATT trial in triple negative or HER2 positive breast cancer. Breast Cancer Res Treat 2013,142(3):549-558. 10.1007/s10549-013-2761-1.
26. Guiu S, Liegard M, Favier L, van Praagh I, Largillier R, Weber B, Coeffic D, Moreau L, Priou F, Campone M, Gligorov J, Vanlemmens L, Trillet-Lenoir V, Arnould L, Coudert B: Long-term follow-up of HER2-overexpressing stage II or III breast cancer treated by anthracycline-free neoadjuvant chemotherapy. Ann Oncol 2011,22(2):321-328. 10.1093/annonc/mdq397.
27. Spector NL, Blackwell KL: Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2009, 27:5838-5847. 10.1200/JCO.2009.22.1507.
28. Kundu N, Fulton AM: Interleukin-10 inhibits tumor metastasis, downregulates MHC class I, and enhances NK lysis. Cell Immunol 1997, 180:55-61. 10.1006/cimm.1997.1176.
29. Hamidullah, Changkija B, Konwar R: Role of interleukin-10 in breast cancer. Breast Cancer Res Treat 2012,133(1):11-21. 10.1007/s10549-011-1855-x.
30. Hurvitz SA, Betting DJ, Stern HM, Quinaux E, Stinson J, Seshagiri S, Zhao Y, Buyse M, Mackey J, Driga A, Damaraju S, Sliwkowski MX, Robert NJ, Valero V, Crown J, Falkson C, Brufsky A, Pienkowski T, Eiermann W, Martin M, Bee V, Marathe O, Slamon DJ, Timmerman JM: Analysis of Fcgamma receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients. Clin Cancer Res 2012, 18:3478-3486. 10.1158/1078-0432.CCR-11-2294.
31. Gianni L: The "other" signaling of trastuzumab: antibodies are immunocompetent drugs. J Clin Oncol 2008, 26:1778-1780. 10.1200/JCO.2007.15.7404.
32. Javeed A, Ashraf M, Riaz A, Ghafoor A, Afzal S, Mukhtar MM: Paclitaxel and immune system. Eur J Pharm Sci 2009, 38:283-290. 10.1016/j.ejps.2009.08.009.